# DyNAbind

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dynabind

- Industry: Pharmaceuticals
- Headquarters: Dresden, Germany
- Website: www.dynabind.com
- Latest round: Seed (May 8, 2019)
- Investors on record: 3

## About

DyNAbind GmbH specializes in innovative DNA-Encoded Library (DEL) technologies that enhance drug discovery processes for pharmaceutical and biotechnology companies through patented tools and high-quality libraries.Founded in 2017 in Dresden, Germany, DyNAbind GmbH focuses on advancing drug discovery by providing DNA-Encoded Library technologies. The company was established by founder Luca Mannocci, and as of the most recent deal on May 8, 2019, it secured seed funding from investors including High-Tech Gründerfonds and Technologiegruenderfonds Sachsen. Michael Thompson currently serves as CEO of the company.DyNAbind specializes in the development of advanced DNA-Encoded Library (DEL) technologies designed to streamline and enhance drug discovery processes. Their core offerings include patented tools and high-quality libraries that significantly expand chemical space coverage and improve the reliability of hit identification. One of their standout innovations is a novel DNA architecture that generates new structures to create stronger binders, complemented by a dual-DNA presentation system that markedly improves signal-to-noise ratios by over 30-fold. The company also features a proprietary path-coding system that enhances the informatics pipeline, effectively reducing false positives and negatives in hit identification by increasing usable sequences by over 37%. DyNAbind primarily serves pharmaceutical and biotechnology companies engaged in drug discovery across various global markets, including North America, Europe, and Asia.In the most recent year, 2022, DyNAbind reported a revenue of USD 850,415.70. The company's revenue model is structured around partnerships and collaborations with pharmaceutical and biotechnology firms, where clients engage with DyNAbind to utilize its innovative DEL technologies and tools. Transactions typically involve contractual agreements for access to high-quality libraries and informatics solutions, allowing clients to validate compounds and streamline their drug discovery processes. Revenue-generating activities may include service fees for specific projects or subscriptions for ongoing access to their technological offerings, ensuring a consistent revenue flow from its client base while fostering long-term partnerships within the industry.DyNAbind plans to utilize its most recent funding from May 2019 to support the development of upcoming products and expand into new geographic regions. Specific markets targeted for expansion include North America and Asia, with plans to launch new DEL technologies intended to optimize drug discovery by the end of 2024. The funding will also facilitate the enhancement of their proprietary systems to further improve client services and outcomes.

## Funding rounds

- Seed, May 8, 2019 — CFH Management, High-Tech Gruenderfonds, TUDAG

## Investors

- CFH Management (https://capitalatlas.ai/funds/cfh-management) — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- TUDAG — Seed